Equities research analysts at Evercore ISI assumed coverage on shares of TESARO, Inc. (NASDAQ:TSRO) in a research note issued on Wednesday, Marketbeat reports. The firm set an “in-line” rating and a $121.00 price target on the biopharmaceutical company’s stock. Evercore ISI’s target price indicates a potential upside of 7.09% from the company’s current price.

A number of other research firms have also recently weighed in on TSRO. Oppenheimer Holdings, Inc. assumed coverage on shares of TESARO in a research report on Thursday, May 25th. They issued an “outperform” rating and a $183.00 price objective for the company. Cann reissued an “outperform” rating on shares of TESARO in a research report on Wednesday, May 24th. Credit Suisse Group set a $198.00 price objective on shares of TESARO and gave the company a “buy” rating in a research report on Monday, June 5th. FBR & Co decreased their price objective on shares of TESARO from $200.00 to $195.00 and set a “mkt perform” rating for the company in a research report on Monday, June 5th. Finally, Wedbush raised shares of TESARO to an “outperform” rating and set a $168.00 price objective for the company in a research report on Monday, June 5th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $173.83.

TESARO (NASDAQ:TSRO) traded up 1.16% during mid-day trading on Wednesday, reaching $114.30. The company’s stock had a trading volume of 154,170 shares. The stock’s 50 day moving average price is $127.76 and its 200 day moving average price is $148.43. The stock’s market capitalization is $6.19 billion. TESARO has a 1-year low of $83.26 and a 1-year high of $192.94.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.52) by $0.30. The firm had revenue of $29.50 million during the quarter, compared to analysts’ expectations of $18.61 million. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The business’s quarterly revenue was down 17.6% on a year-over-year basis. During the same period in the previous year, the company earned ($1.28) earnings per share. Analysts expect that TESARO will post ($8.74) EPS for the current fiscal year.

WARNING: “TESARO, Inc. (TSRO) Coverage Initiated at Evercore ISI” was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/08/16/tesaro-inc-tsro-research-coverage-started-at-evercore-isi.html.

In related news, VP Edward C. English sold 8,500 shares of the stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the sale, the vice president now owns 5,396 shares in the company, valued at $748,155.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 40.50% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Botty Investors LLC purchased a new position in TESARO during the second quarter valued at approximately $140,000. Nordea Investment Management AB purchased a new position in TESARO during the second quarter valued at approximately $167,000. Meeder Asset Management Inc. purchased a new position in TESARO during the first quarter valued at approximately $177,000. Oppenheimer Asset Management Inc. boosted its position in TESARO by 3,042.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,430 shares during the period. Finally, BB&T Securities LLC purchased a new position in TESARO during the second quarter valued at approximately $222,000.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.